

Control of Assertance Standard Object Concept,"

# **Fax Cover Sheet**

To:	Department of Labo	From: Gary S. Vander Boegh
Fax:	(904) 357-4704	Date: 04/13/2012
Phone:		Pages: <u>JU</u> Pages including the Cover Sheet
Re:	Warren Scott xxx-xx-7351	CC:
□ Urgent	X For Review	□ Please Comment X Please Reply □ Please Recycle
Comment	ts:	
	6/()	
	<i>y</i>	

### Survivor's Claim for Benefits Under the Energy Employees Occupational Illness Compensation Program Act



U.S. Department of Labor
Office of Workers' Compensation Programs
Division of Energy Employees Occupational
Illness Compensation

Note: Please read the instructions on page 3 before completing this form. Provide all information OMB Control No: 1240-0002 requested below, and sign and date the bottom of Page 2. Do not write in the shaded areas. Expiration Date: 10/31/2013						
Deceased Employee Information (please print clearly)						
1. Name (Last, First, Middle Initial)		. Social Security Nu	mber			
Scott Warren E	Male Female					
4. Date of Birth 5. Date of Death	6. Was an autopsy performe	ed on the employee?				
	YES - List Medical Facility:					
Month Day Year Month Day Year	■ NO □ DON'T KNOW					
Survivor Information (please print clearly)						
7. Name (Last, First, Middle Initial)		. Social Security Nu	mber			
Scott Betty	☐ Maie ☒ Female					
10. Date of Birth 11. Your relationship to the						
X spouse child	step-child	adopted child				
Month Day Year parent grandp	arent grandchild 13. Telephon	Other:	<u></u>			
12. Address (Street, Apt. #, P.O. Box)	13. Telephon	e Humbers				
(City, State, ZIP Code)	a. Home:	,				
(City, State, ZIP Code)	h Other (	) -				
14. Identify the Diagnosed Condition(s) Being Cl	b. Other: (	hack have and list specific	diagnosis)			
	anned as Work-Related (		e of Diagnosis			
Cancer (List Specific Diagnosis Below)		Month	Day Year			
a.						
b.						
<u>c.</u>						
d.						
X Chronic Beryllium Disease (CBD)						
☐ Chronic Silicosis						
Other Work-Related Condition(s) due to exposure to tox	ic substances or radiation (List	Specific Diagnosis Below)				
b.						
C.						
d. Awards and Other Information						
16. Have you or the deceased employee filed a lawsuit based on exp	posure to radiation, beryllium, asbe	stos or any other	☐ YES × NO			
17. Have you or the deceased employee filed any state workers' compensation claims in connection with any condition(s) you claim in Item 14?						
18. Have you, the deceased employee, or another person received a settlement or other award in connection with a lawsuit or state workers' compensation claim described in questions 16 or 17?						
19. Have you either pled guilty to or been convicted on any charges connected with an application for or receipt of federal or state workers' compensation?						
20. Have you or the employee applied for an award under Section 5	of the Radiation Exposure Compe	nsation Act (RECA)?	☐ YES 🗷 NO			
If yes, provide RECA Cla	im #:					
21. Have you or the employee applied for an award under Section 4	of RECA?		☐ YES 🗵 NO			

Ot	her Potential Survivors			
22.	List any person(s) who may also qualif	y as a survivor of the d	eceased employee and include the foll	owing information:
	Name	Relationship to the deceased employee	Address	Phone Number(s)
a.				Home: Other:
b.				Home: Other:
c.				Home: Other:
d.				Home: Other:
e.				Home: Other:
f.				Home: Other:
g.				Home: Other:
h.				Home: Other:
i,				Home: Other:
j.				Home: Other:
Su	rvivor Declaration			
Any compto cive punits report under Justin Office instit	person who knowingly makes any false statement, representation as provided under EEOICPA or who knowing or administrative remedies as well as felony crimished by a fine or imprisonment or both. Any change the dimmediately to the district office responsible for EEOICPA and affirm that the information I have pice to release any requested information, including in e of Workers' Compensation Programs (OWCP). Furtuition, corporation, or government agency, including J.S. Department of Labor, Office of Workers' Compe	ngly accepts compensation to nal prosecution and may, unce to the information provided r the administration of the cla rovided on this form is true. Information related to my REC rthermore, I authorize any ph the Social Security Administr	which that person is not entitled is subject der appropriate criminal provisions, be on this form once it is submitted must be im. I hereby make a claim for benefits If applicable, I authorize the Department of A claim, to the U.S. Department of Labor, ysician or hospital (or any other person,	Resource Center Date Stamp
			_	Form EE-2 November 2009

November 2009

#### COMMONWEALTH ENVIRONMENTAL SERVICES, LLC

"A Native American - Woman Owned Commany"

Gary Vander Boegh, Vice President Commonwealth Environmental Services, LLC 4645 Village Square Drive, St. F Paducah, Kentucky 42001 Telephone: (270) 450-0850

Facsimile: (270) 450-0858

April 13, 2012

U. S. Department of Labor, 400 West Bay Street, Suite 722 Jacksonville, FL 32202 Facsimile 904-357-4785

Employee: Warren Scott
Claimant: Betty Scott
File Number: XXX-XX -7351

#### To Whom It May Concern:

As "Authorized Representative" (AR) for claimant Betty Scott, I hereby submit the following medical evidence in support of the Chronic Beryllium Disease (CBD) claim under Part B and E of the Act based on statutory requirements 42 USC § 73841 (13) (B) as follows:

- (B) For diagnoses before January 1, 1993, the presence of—
  - (i) <u>occupational or environmental history</u>, or epidemiologic evidence of beryllium exposure; and
    - (iii) any three of the following criteria:
      - (I) Characteristic chest radiographic (or computed tomography (CT)) abnormalities.
      - (II) Restrictive or obstructive lung physiology testing or diffusing lung capacity defect.
      - (III) Lung pathology consistent with chronic beryllium disease.

# (IV) Clinical course consistent with a chronic respiratory disorder.

(V) Immunologic tests showing beryllium sensitivity (skin patch test or beryllium blood test preferred).

The Department of Labor has further stated, "For beryllium disease prior to January 1, 1993, a specific diagnosis of CBD IS NOT REQUIRED (emphasis added.)"....

Per Chapter 2-700.4 (September 2004) of the Federal (EEOICPA) Procedure Manual, "To determine whether to use the Pre or Post 1993 CBD criteria, the medical evidence must demonstrate that the employee was either treated for, tested or diagnosed with a chronic respiratory disorder. If the earliest dated document is prior to January 1, 1993, the pre-1993 CBD criteria may be used. Once it is established that the employee had a chronic respiratory disorder prior to 1993, the CE is not limited to use of medical reports prior to 1993 to meet the three of five criteria."

The Paducah Gaseous Diffusion Plant was a DOE facility from 1952 to July 28, 1998 and July 29, 1998 to present (remediation) where radioactive and beryllium materials were present, according to the Department of Energy Office of Worker Advocacy Facility List (<a href="http://www.hss.energy.gov/HealthSafety/FWSP/Advocacy/faclist/findfacility.cfm">http://www.hss.energy.gov/HealthSafety/FWSP/Advocacy/faclist/findfacility.cfm</a>).

Mr. Scott was employed for the Paducah Gaseous Diffusion Plant (PGDP), a covered Department of Energy (DOE) facility. During his employment he worked for Union Carbide, Martin Marietta Energy Systems and Lockheed Martin from February 02, 1953 to January 01, 1995.

Attached is the medical documentation that supports Ms. Scott's claim for CBD.

#### Mr. Scott's Lung Abnormalities that meets Criteria I Pre-1993 Chronic Beryllium Disease:

- X- ray report dated March 20, 1979, states lungs show <u>hilar and parenchymal</u> <u>calcifications unchanged.</u>
- X-ray report dated September 30, 1980, states there is mild fibrosis in the right lower lobe.
- X- ray report dated August 08, 1991; states <u>calcification is present within the aortic arch.</u> The lungs are hyperinflated consistent with COPD. Patchy opacities overlying the aorta just above the diaphragm on the lateral film, which were present on previous exam and would be most consistent with some fibrotic change.
- X- ray report dated September 30, 1998, states **chest demonstrates COPD and chronic fibrosis.**
- X- ray report dated October 19, 1998, states <u>changes of COPD are identifies</u>, with mild interstitial prominence. Scattered granulomata are also identified.

Mr. Scott's Restrictive or Obstructive Lung Physiology Testing or Diffusing Lung Capacity Defect that meets Criteria II Pre-1993 Chronic Beryllium Disease:

- Pulmonary Function Test dated November 28, 1989, FEV1 77%.
- Pulmonary Function Test dated August 08, 1991, FEV1 68%.
- Pulmonary Function Test dated August 10, 1992, FEV 72%.

- Pulmonary Function Test dated August 11, 1993, FEV1 72%.
- Pulmonary Function Test dated August 09, 1994, FEV1 76%.
- Pulmonary Function Test dated November 08, 1999, FEV1 74%.
- Pulmonary Function Test dated March 15, 2001, FEV1 65%.

# Mr. Scott's Clinical Course Consistent with a Chronic Respiratory Disorder & Treatment that meets Criteria IV Pre-1993 Chronic Beryllium Disease:

- Combivent
- Singulair
- Serevent
- Lasix

Based on the medical evidence presented, Ms. Scott has met the statutory and regulatory burden of proof for her EEOICPA Part B & E claim and be compensated in the amount of \$150,000 for Part B and \$125,000 Part E.

If you have any questions or concerns, please feel free to contact me at 270-559-1752 or 270-450-0850.

Directory,

Gary S. Vander Boegh

"Authorized Representative"

Vice President- Commonwealth Environmental Services, LLC.



# Memorandum from DEEOIC Medical Director Regarding Causal Relationship Between Established CBD and Other Respiratory Disorders

# Memorandum

Date:

08/25/2005

To:

Peter Turcic, Director of DEEOIC, Department of Labor

From:

Sylvie I. Cohen, MD, MPH

RE:

Chronic Pulmonary Diseases

This memo is to address the rationale between the accepted medical condition under part B of the program for Chronic Beryllium Disease (CBD) and its contribution and aggravation of other chronic pulmonary diseases.

CBD is considered to be a disease that is involved with the destruction of viable pulmonary tissue that normally aides an individual in the process of gas exchange and blood oxygenation.

There are other chronic pulmonary diseases that are involved with lung tissue destruction or replacement that for the purpose of this memo we shall call "Other Chronic Pulmonary Diseases." Diseases that should be considered as members of this set are: asbestosis, silicosis, Chronic Obstructive Pulmonary Disease (COPD), emphysema, and pulmonary fibrosis.

Since both CBD and Other Chronic Pulmonary Diseases share in the destruction and or replacement of viable lung tissue, it can be concluded that the presence of CBD contributed or aggravated one of the illnesses named in the list of Other Chronic Pulmonary Diseases which led to an individual's death.

CA-002 PAGE OF1

11. (4).	NION CARBIDE CORPORATION ICLEAR DIVISION
i' sre	
កនេ ឧក០ខ្លួសក្ <sup>ក</sup> ្ ប	?-7351 CMOYZ45
AST NAME	INITEALS W.E.
EX GROUP	A G E
	X-RAY EXAMINATIONS
RE ADING:	
9-30-80 Per	Chest: There is mild fibrosis in the right lower lobe. This should not be of clinical significance. The chest is otherwise, unremarkable.
	PB:ejw

#### CARBIDE AND CARBON CHEMICALS COMPANY

#### PADUCAH, KENTUCKY

#### X-RAY EXAMINATIONS

Medical No. 2015	oolt, Marron	Łówin
Date		Reading

3-20-79 Per Chest: Re-examination in comparison with the last routine film, shows no essential change. The heart is transverse and normal in size and both lungs—show hilar and psrenchymal calcifications unchanged.

Impression: Essentially normal chest.

Mistejw

WESTERN BAPTIST HOSPITAL
WHERE YOUR NEEDS COME FIRST
2501 KENTUCKY AVE
PADUCAH, KENTUCKY 42001

NAME: Scott, W. E.

CHART: 2245 DATE: 08/08/91

#### MARTIN MARIETTA X-RAY REPORT

#### PA & LATERAL CHEST:

Heart is normal in size, contour. Calcification is present within the aortic arch. The lungs are hyperinflated consistent with COPD. Patchy opacities overlying the aorta just above the diaphragm on the lateral film, which were present on previous exam and would be most consistent with some fibrotic change. There is no other evidence of pneumonia.

IMPRESSION:
COPD.

pm

JC/js

DD: 08/13/91 DT: 08/13/91 Jan Crossett, M.D

LOURDES HOSPITAL 1530 LONE OAK ROAD PADUCAH KY, 42003 DEPARTMENT OF RADIOLOGY (502) 444-2177

#### RADIOLOGY REPORT

NAME: SCOTT, WARREN PHYS: BUTLER, DANNY MD

AGE: 65 SEX: M LOCATION: 0334 01

EXAM DATE: 09/30/98 STATUS: ADM IN RADIOLOGY NO: UNIT NO: 134293

BUTLER, DANNY MD P.O. BOX 7626 PADUCAH KY 42002 (502)443-4311

EXAMS: 000192250 CHEST PA/LATERAL

HISTORY: CK LUNG STATUS

CHEST PA/LATERAL: Two view chest demonstrates COPD and chronic fibrosis. There is no evidence of failure, pneumonia, or pleural fluid. On the lateral view, projecting over the heart, I question an enlarging nodular density.

#### IMPRESSION:

1. COPD WITH FIBROSIS.

2. NO EVIDENCE OF PNEUMONIA.

3. ON THE LATERAL VIEW, I QUESTION AN ENLARGING NODULAR DENSITY MEASURING ABOUT 1.5 CM PROJECTING OVER THE HEART. FOLLOWUP CHEST X-RAY IS RECOMMENDED.

REPORTED BY: ROBERT A. GARNEAU, MD

CC: BUTLER, DANNY MD

TECHNOLOGIST: JASON LEDBETTER R.T.(R) TRANSCRIBED DATE/TIME: 09/30/98 (2229)

TRANSCRIPTIONIST: 1488SDG

PRINTED DATE/TIME: 09/30/98 (2340) BATCH NO: 725



NAME: SCOTT, WARREN PHYS: BUTLER, DANNY MD

AGE: 66 SEX: M LOC: CLINICAL

EXAM DATE: 10/19/1998 STATUS: REG REF

RADIOLOGY NO: UNIT NO: 134293

#### RADIOLOGY REPORT

BUTLER, DANNY MD P.O. BOX 7626 PADUCAH KY 42002

(502)443-4311

EXAMS: 000195733 CHEST PA/LATERAL

HISTORY: PNEUMONIA.

CHEST, TWO VIEWS: Frontal and lateral projection chest radiographs were obtained and compared to the prior chest film. Changes of COPD are identified, with mild interstitial prominence. Scattered granulomata are also identified. The lungs are free of acute infiltrates. The heart is within normal limits in size with mild ectasia of the aorta. The pulmonary vasculature is appropriate without evidence of heart failure. The nodular density previously described on the lateral film is less conspicuous on today's study and is compatible with superimposition of normal structures. The bony structures are intact.

#### **IMPRESSION**

1. COPD.

2. NO ACUTE CARDIOPULMONARY PROCESS.

REPORTED BY: PAUL JOHNSON, MD

CC: BUTLER, DANNY MD

TECHNOLOGIST: STUDENT TECHNOLOGIST TRANSCRIBED DATE/TIME: 10/19/1998 (1553)

TRANSCRIPTIONIST: KAL2314

PRINTED DATE/TIME: 10/19/1998 (1652) BATCH NO: 1208



## **PULMONARY FUNCTION**

IAME			DEPT.	EMP	LOYEE NO.		AGE			
WARREN E	DVIN SCO	OTT	5743 <b>-</b> 1	1 22	2 <u>45-00486</u>	8				
11-28-89	PEAK	FEV 1.0	FEV 3.0	FVC	FEV 1.0 %	FEV 3.0 %	FEF 200-1200	FEF 25%-75%	MVV	1
MEASURED		2.82		3.68	77%			2.51		
PREDICTED		3.50	i	4.45				4.37		
% OF PREDICTED		817.	! !	837.	,	ļ		587.		:
8-8-91	PEAK	FEV 1.0	FEV 3.0	FVC	FEV 1.0 %	FEV 3.0 %	FEF 200-1200	FEF 25%-75%	MVV	:
MEASURED		2.02		2.99	687-			1.26		į
PREDICTED		3.34_		4.25	:			4,22		!
% OF PREDICTED		607		707.				30%		
8-10-92	PEAK	FEV 1.0	FEV 3.0	FVC	FEV 1.0 %	FEV 3.0 %	FEF 200-120	FEF 25%-75%	MVV	:
MEASURED		2.08		2.89	727.			1,56		
PREDICTED		3.32		4.22				4.19		
% OF PREDICTED		637.		687.		ļ		377.		
8-11-93	PEAK	FEV 1.0	FEV 3.0	FVC	FEV 1.0 %	FEV 3.0 %	FEF 200-1200	FEF 25%-75%	MVV	
MEASURED		1.97		2.75	72			1.51		:
PREDICTED		3.29		4.19				4.16		
% OF PREDICTED		,60		66				36		i
* has UR	L		· · · · · · · · · · · · · · · · · · ·							
8-9-94	PEAK	FEV 1.0	FEV 3.0	FVC	FEV 1.0 %	FEV 3.0 %	FEF 200-1200	FEF 25%-75%	MV∨	
MEASURED		2.24		2.94	767.			1.90		
PREDICTED		3.13		4.00				4.02		
% OF PREDICTED		727.		747.	1			477.		
DATE	PEAK	FEV 1.0	FEV 3.0	FVC	FEV 1.0 %	FEV 3.0 %	FEF 200-1200	FEF 25%-75%	MVV	
MEASURED		; E								:
				;	1			1	,	

UCN-11491 (1 2-80)

% OF PREDICTED

#### Pulmonary Function Laboratory Jackson /chase Medical Center 1099 Medical Center Circle Mayfield, KY 42066 (270)251-4120

Name: Scott, Warren

ld: 405427351

Date: 11/08/99

Age: 67

Race: Caucasian

Gender: Male

Height(in): 70 Weight(lb): 250 Temp: 23

PBar: 766

Physician: Randel Gibson, D.O.

Technician: M Ragsdale, RRT CPFT

Diagnosis:

		Ref	Pre	% Ref	Post	% Ref	%Chg
irometry							
FVC	Liters	4.24	2.75	65			
FEV.5	Liters	2.13	1.22	57			
FEV.5/FVC	%	50	44				
FEV1	Liters	3.11	1.68	54			
FEV1/FVC	%	74	61				
FEV3	Liters		2,23				
FEV3/FVC	%	97	81				
FEF25-75%		2.79	0.83	30			
IsoFEF25-75	5 L/sec	2,79	0.83	30			
FEF75-85%	∐sec	0.58	0.16	28			
FEF25%	L/sec		2.84				
FEF50%	L/sec	4,18	1.04	25			
FEF75%	L/sec	1.49	0.20	14			
FEF80%	L/sec		0.15				
FEF200-120	0 L/sec	6.49	2.27	35			
PE=	L/sec	8.37	3.01	36			
FET25-75%	Sec	0.54	1.87	347			
FET100%	Sec		14.54				11 111
FIVC	Liters	4.24	0.09	2			SECE 1009
Vol Extrap	Liters		0.13			16	009 1111
FVL ECode			001000			//	1 1993
MVV	⊔min	131	53	40		1	NOV 15 1999
MVV Length			12				ILAN NOT
f	BPM		105				
MVV ECode			111000				
							II The
							\

Patient effort - satisfactory. Calibration was performed prior to testing and found to be within acceptable limits. No adverse reactions to the procedure(s) were suspicioned and/or identified.

<sup>1)</sup> There is a moderate obstructive lung defect. The airway obstruction is confirmed by the decrease in flow rate at peak flow and flow at 50% and 75% of the flow volume curve.

<sup>2)</sup> An additional restrictive lung defect cannot be excluded by spirometry alone. On the basis of this study, more detailed pulmonary function testing may be useful if clinically indicated.

# 1530 LONE OAK ROAD PADUCAH, KY 42002 PULMONARY NCTION LAB

Name: SCOTT, WARREN E

Gender: Male

Race: Caucasian Age: 68 Height(in): 69 Weight(lb): 265
Any Info: COMPLETE LUNG VOLUMES

ld: 134293 Date: 03/15/01

PBar: 741 Temp: 21 Physician: DR. J. CLARKE

Technician: Lesia Wells CRT CPFT

Any Info: COMPLETE LUNG VOLUMES					Technician: Lesia Wells CRT CPT1				
				PRE-RX		POST-RX			
Spirome	etry (BTPS)	PRED	В	EST %PRED		BEST %PRE		% Chg	
FVC FEV1 FEV1/FVC FEF25-75%	Liters Liters %	3.96 3.14 79 3.15	2.70 1.57 58 0.57	68 50 18	2.98 1.93 65 0.97	75 62 31	10 23 70		
FEF50% PEF MVV	L/sec L/sec L/min	3.94 8.10 127	0.80 4.21 59	20 52 47	1.44 4.45 61	37 56 48	79 6 3		
Gas Dilu									
Lung Vo	lumes (BTPS)				0.04	76	-20		
VC TLC RV RV/TLC	Liters Liters Liters %	3.96 6.30 2.44 40	3,76 7,11 3,36 47	95 113 138	3.01	76	-20		
FRC Dil ERV IC	Liters Liters Liters	2.94	3.63 0.22 3.41	124	0.25 2.65		12 -22		
Plethysr Lung Vo	nograph Jumes (Btp	s)							
Vtg VC TLC RV RV/TLC	Liters Liters Liters Liters %	3.96 6.30 2.44 40	5.34 3.76 7.11 3.36 47	95 113 138					
FRC PL ERV IC FRC PL-DI	Liters Liters Liters	2.94	3.70 0.22 3.41	126					
million in	_								
Diffusion DLCO DL Adj DLCO/VA VA	mUmin/mmHg mUmin/mmHg 1/min/mmHg Liters	26.7 26.7 3.59	23.9 26.5 4.06 5.89	90 99 113					
Resistar	nce								
	cmH2O/L/sec cmH2O/L/sec cmH2O/L/sec cmH2O/L/sec L/sec/cmH2O cmH2O/L/sec 1/cmH2O sec	4.75	6.76 3.38 11.05 5.37 0.186 28.63 0.035 5.34	332 26 602 17					
	OZ CONEIDENCE	INTERVAL	Моп	n Set: Knudson	(1983)		Version: IV	'S-0101-01-6	

( ) = OUTSIDE 95% CONFIDENCE INTERVAL

## DANNY N. BUTLER, M.D.

Interno 1edicine - Board Certified

2601 Kentucky Avenue, Suite 301 Paducah, Kentucky 42003

Telephone (270) 443-2900

Paducah, Kentucky 42	2003	MEDICATION	ON LIST	resepric	one (270) 4	43-2900
Patient Name: \\\	Avon Scott	Pho	ne:	Pharmacy: _		
Allergies: <u>Ominu</u>	col				<u></u>	
1/21/01 LIN	U	GULAR / DAILY	MEDICATIONS			
MEDICATION	DOSAGE	AMOUNT	PHARMACY	DATE REFILLED	DATE D/C	WRITTE BY
-Humolog	75 40490.m					
Combient inh	11 p. 65 Sid	30x5	Bardurli	3/29/01		B
K-Dun - Yasiy	20mg Tgd	30×11	Danduece	6/7/01		ms
Toshii	10mg Tgd	30 XII	Bardwell	12/07/00	Whethor	1/10
Ditipo Xc	5mg TSid	#30X11	Bardwell	11/27/00		ms
Laborator	200mg tibe	inox lyn	Bandwell	8/30-101		m5
ASA	90 75/25 301 p.m.					
Humalog	75/25 300 p.m.					
1118 whin Head les	) are dir	1box xlyr	written	1/23/01		rrs_
Serevent Un						1,00
Glucometer Elitet	eptistrips asder	1 DOX X lyr	Bardwee	6/7/01		ms
Zestril	21 mgi (CD)					
LUVITA	20mg Tgcl					
	SI	HORT-TERM MI	EDICATIONS			
allega	60mmin pra	<b>4</b> 00	plamples	5/21/01	٠	6
· 0	V 1					
	į į	Į.		1	í	1

#### PTTSRESS NOTES .COTT #49904JSC MARCH 26, 2001

SUBJECTIVE: The patient's PFTs did show a moderate obstructive ventilatory defect with improvement post bronchodilator. I told him that based on this, he certainly could have some component of asthma. His diffusion capacity was normal. Again, based on this he appears to have predominantly reversible airways disease and not emphysema. He does not have evidence of restrictive either even in view of his HX of sleep apnea.

OBJECTIVE:

WEIGHT: 265

**BLOOD PRESSURE: 172/84** 

PULSE: 76

CHEST: Clear. No adventitious sounds heard. Breath sounds are somewhat decreased.

LAB DATA: N/A

IMPRESSION: COPD with a reversible component.

PLAN: Continue Combivent 2 puffs qid PRN. We will add Aerobid Inhaler 2 puffs bid, gargle after using, samples given. Singulair 10-mg HS, samples given. I told him that hopefully over the next several weeks, he will notice some improvement in pulmonary status with the combination of inhaled steroids and Singulair. I will see him back in the office for F/V in about a month.

Jeffreys, Clarke, M.D.

JSC/rlt

COPY: Danny Butler, MD Maile O 8-6-01 Vach

PROGRESS NOTES WARREN SCOTT #49904JSC JUNE 4, 2001

SUBJECTIVE: The patient states that Serevent didn't seem to help him. Really, he states that Combivent does the best for him. He has a lot of allergy type symptoms with post nasal drip and episodes of sneezing and cough related to this. His wife states that when he mows the lawn he usually wears a mask and sometimes does not and seems to do worse when he does not wear a mask.

OBJECTIVE:

- WEIGHT: 259.5

BLOOD PRESSURE: 160/82

PULSE: 72

CHEST: Clear. No adventitious sounds heard.

HEENT: Edema in the nasal mucosa.

LAB DATA: N/A

IMPRESSION: 1. COPD with a reversible component. He has not responded well to inhaled steroids, Singulair, or Serevent.

2. Rhinitis with a possible component of sinobronchial syndrome.

PLAN: We will try him on Nasonex nasal spray 2 sprays each nostril daily, samples given. If this does well for him rall me and we will get him a prescription. I will see him back in several months otherwise.

Jeffrey S. Clarke, M.D.

JSC/rlt

COPY: Danny Butler, MD Mailed 8-6-01 Vash

04/13/2012 FRI 09:52	FAX	village business center	4001
	*****	*****	
	*** FAX TX F	REPORT ***	
	******	******	
	TRANSMISS	EION OK	
	JOB NO.	1593	
	DEPT. ID	151	
	DESTINATION ADDRESS	919043574704	
	PSWD/SUBADDRESS		
	DESTINATION ID		
	ST. TIME	04/13 09:45	
	USAGE T	06' 38	
	PGS.	16	
	RESULT	OK	

COMMONWEALTH ENVIRONMENTAL SERVICES, LLC

# **Fax Cover Sheet**

10:	Department of Lat	oor From: Gary S. Vander Boegn
Fax:	(904) 357-4704	Date: 04/13/2012
Phone:	A STATE OF THE STA	Pages: Jie Pages including the Cover Sheet
Re:	Warren Scott xxx-xx-7351	CC:
□ Urgent	X For Review	☐ Please Comment X Please Reply ☐ Please Recycle
Comment	rs:	
	[A],	

Ø<sub>001</sub>

JOB NO.
DEPT. ID

1593 151

16

ST. TIME 04/13 09:37

PGS.

SEND DOCUMENT NAME

TX IMCOMPLETE ----

TRANSACTION OK

919043574704

ERROR

\_\_\_\_

COMMONWEALTH ENVIRONMENTAL SERVICES, LLC

# LC

## **Fax Cover Sheet**

To:	Department of Laborate	From: Gary S. Vander Boegh
Fax:	(904) 357-4704	Date: 04/13/2012
Phone		Pages: 14 Pages including the Cover Sheet
Re:	Warren Scott xxx-xx-7351	CC:
□ Urgent	X For Review	☐ Please Comment X Please Reply ☐ Please Recycle
Commen	ts:	